Prognostic factors for refractory pheochromocytoma and paraganglioma after 131I-metaiodobenzylguanidine therapy.

Tomo HiromasaHiroshi WakabayashiDaiki KayanoAnri InakiSatoru WatanabeHiroshi MoriNorihito AkataniTakafumi YamaseYuji KunitaShintaro SaitoSeigo Kinuya

Published in: Annals of nuclear medicine (2021)

Response to repeated 131I-mIBG treatment can be a strong predictor of prognosis after initial 131I-mIBG therapy for refractory PPGL. Repeated 131I-mIBG therapy may be a good option for controlling refractory PPGL.

Keyphrases

prognostic factors
stem cells
mesenchymal stem cells
cell therapy